Effects of a synthetic factor Xa inhibitor (JTV-803) on various laboratory tests.
Synthetic direct inhibitors of factor Xa are capable of prolonging the global anticoagulant assay times in a concentration-dependent fashion. The relative degree of thrombin generation inhibition at an equivalent prolongation is not similar to the results observed with heparins and oral anticoagulant drugs. In addition, the direct factor Xa inhibitors prolong the Russell's viper venom test (RWT) and Heptest clotting times. Ecarin clotting time (ECT) and thrombin time (TT) remain unaffected. The kinetics of factor Xa inhibition are markedly different than those observed with pentasaccharide and heparins. Therefore, the methods developed for heparins and pentasaccharides may not be applicable for the monitoring of factor Xa inhibitors. To test the feasibility of using the prothrombin time (PT), International Normalized Ratio (INR), activated partial thromboplastin time (aPTT), Heptest, thrombin time, RVVT, ECT, and a modified anti-Xa amidolytic assay, to monitor a synthetic factor Xa inhibitor, normal human pool plasma samples were spiked with a synthetic factor Xa inhibitor in the concentration range of 0 to 1 microg/mL and 0 to 25 microg/mL. Different laboratory tests were performed and INR and other ratios were calculated. The anticoagulant effects on whole blood were measured using the activated clotting time (ACT). Further studies on the effect of factor Xa inhibitor on platelet aggregation; factor II, VII, and X functional levels; and fibrinopeptide A (FPA) generation were carried out at equivalent INR levels in comparison to oral anticoagulant and antithrombin agents. FPA generation at equivalent anticoagulant level in comparison to heparin (twice the baseline) was also carried out. Factor Xa inhibitor produced a concentration-dependent prolongation of the ACT. ACT was doubled at a concentration of 4 to 5 microg/mL. There was a marked difference in the prolongation of the PT by a synthetic factor Xa inhibitor dependent on the ISI of the PT reagent used. When the results were calculated to determine INR, marked variations were noted between the recombinant thromboplastin and rabbit brain thromboplastin. The rabbit brain thromboplastin reagent gave markedly high INR values. Similar results were observed when different aPTT reagents were studied. In the anti-Xa assay, modification of the incubation time was employed to extend the proper sensitivity range. These studies warrant further investigation to understand the mechanism of action of factor Xa inhibitors.
Tobu
Mahmut
M
Loyola University Medical Center, Maywood, Illinois 60153, USA.
Iqbal
Omer
O
Hoppensteadt
Debra A
DA
Shultz
Christopher
C
Jeske
Walter
W
Fareed
Jawed
J
D000925:Anticoagulants / Q000494:pharmacology*; D001780:Blood Coagulation Tests / Q000592:standards; D025901:Carboxypeptidase B2 / Q000097:blood; D004305:Dose-Response Relationship, Drug; D065427:Factor Xa Inhibitors; D005344:Fibrinopeptide A / Q000096:biosynthesis; D006801:Humans; D019934:International Normalized Ratio / Q000592:standards*; D007546:Isoquinolines / Q000494:pharmacology; D008074:Lipoproteins / Q000097:blood; D010880:Piperidines / Q000494:pharmacology; D010974:Platelet Aggregation / Q000187:drug effects; D011725:Pyridines / Q000494:pharmacology; D015842:Serine Proteinase Inhibitors / Q000494:pharmacology; D044005:Tetrahydroisoquinolines
C442639:4-((2-amidino-1,2,3,4-tetrahydroisoquinolin-7-yloxy)methyl)-1-(4-pyridinyl)piperidine-4-carboxylic acid monomethanesulfonate trihydrate; D000925:Anticoagulants; D065427:Factor Xa Inhibitors; D007546:Isoquinolines; D008074:Lipoproteins; D010880:Piperidines; D011725:Pyridines; D015842:Serine Proteinase Inhibitors; D044005:Tetrahydroisoquinolines; C051928:lipoprotein-associated coagulation inhibitor; D005344:Fibrinopeptide A; D025901:Carboxypeptidase B2